Abstracts Book - IMRC 2018

Summary: Heart Disease and Stroke Statistics—2016 Update. Circulation,
133(4), pp.447-454.
2. Colmenares, Gabriel, Agudelo, Liliana, Quintero, Yeixon, & Hoyos, Lina.
(2017). Evolución de los stents coronarios liberadores de fármacos, de la
primera a la cuarta generación. CES Medicina, 31(2), 163-
71. https://dx.doi.org/10.21615/cesmedicina.31.2.5
3. com. (2018). Boston Scientific gets the first (partially) bioabsorbable stent
to FDA approval | FierceBiotech. [online] Available at:
https://www.fiercebiotech.com/medical-devices/boston-scientific-getsfirst-partially-bioabsorbable-stent-to-fda-approval
[Accessed 1 Mar.
2018].
4. Colmenares, G., L. Agudelo, R. Pinal, and L. Hoyos. “Production of
Bioabsorbible Nanoparticles of Polycaprolactone by Using a Recirculating
System.” Pp. 395–98 in TechConnect World Innovation
Conferences. TechConnect. Retrieved (https://briefs.techconnect.org/wpcontent/volumes/TCB2017v1/pdf/178.pdf)
5. Colmenares Roldán, Gabriel Jaime et al. 2018. “Production of
Polycaprolactone Nanoparticles with Low Polydispersity Index in a
Tubular Recirculating System by Using a Multifactorial Design of
Experiments.”Journal of Nanoparticle Research 20(3):68. Retrieved
(http://link.springer.com/10.1007/s11051-018-4168-8).
6. Boston Scientific. Boston Scientific recibe la aprobación de la FDA para
SYNERGYTM Bioabsorbable Polymer-Drug Stent System [Internet]. 5 de
octubre de 2015. 2015. Disponible en:
http://news.bostonscientific.com/2018-03-03-Boston-Scientific-Receives-
FDA-Approval-For-SYNERGY-Bioabsorbable-Polymer-Drug- Eluting -
Stent- Sistema
Keywords: Nanocapsules, PLGA, Biocompatibility
Presenting authors email: isabelgallegogaona@hotmail.com